Company
Pangea Bio
Developing novel neuroplastic therapeutics to treat central nervous system disorders
Also known as Pangea Botanica Ltd
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Pangea Botanica Ltd
Claim, correct or request removal
Record updated 28 September 2026
About
We are a clinical stage biotech company. Our lead R&D program focuses on activating the Tropomyosin receptor kinase B (TrkB) receptor pathway, which promotes neuronal survival and synaptic plasticity. Our lead candidate OT-003 and fast follower OT-1xx series have generated compelling data in a variety of central nervous system disorders with significant unmet need.
Funding snapshot
- Latest round
- Grant2025-10-20
Funding rounds
- Grant
- 2025-10-20
- Grant
- 2024-08-22
Loading relationship preview